Microbiology Laboratory, General Hospital, Policlinico, Mangiagalli and Regina Elena Foundation, Milan, Italy.
Blood Transfus. 2011 Apr;9(2):162-6. doi: 10.2450/2011.0158-09. Epub 2011 Jan 17.
Current European regulations require a deferral period of 6 months or 3 years, depending on the risk of exposure, for prospective blood donors at risk of malaria. This period may be reduced to 4 months if an immunological or molecular genomic test is negative at each donation, but Italian regulations have not adopted this provision. As cases of transfusion-transmitted malaria have been recorded in medical literature in blood donors deferred for 3 years and not tested, the Immunohematology and Transfusion Centre of the Ca' Grande Polyclinic Hospital in Milan decided to introduce immunological testing for all donors at risk of malaria.
Four hundred and twelve blood donors at risk of malaria, who had lived in a malarial area during the first 5 years of life or for more than 6 consecutive months, were tested for malarial antibodies using an enzyme immunoassay kit. The kit (Malaria EIA, Newmarket, UK) uses four recombinant antigens specific for P. falciparum and P. vivax and with cross-reactivity for P. ovale and P. malariae. The kit detects total immunoglobulin antibodies against P. falciparum and P. vivax and shows 80% cross-reactivity with P. ovale and 67% with P. malariae. Antibody-positive samples were further checked by an immunochromatographic test for P. falciparum, P. vivax, P. ovale and P. malariae antigens and by haemoscopy (thin film and thick smear).
Italian citizens accounted for 16.8% (69/412) of the whole group of donors examined. We found that 8.7% of the donors who were classified as being at risk of malaria were positive for total immunoglobulin antibodies. Only one Italian citizen resulted positive for the test. The positive candidates were deferred from blood donation. None of the antibody-positive donors was confirmed positive by the immunochromatographic test and by haemoscopy.
The introduction of a malarial screening test in the assessment of blood donor eligibility may increase the safety of blood donations, but could further reduce blood availability. If immunological testing were to be accepted nationally as a valid method of assessing the risk of malaria, more than 90% of the donors who are currently deferred for 3 years could be accepted 4 months after their last visit to an endemic area, thus increasing the availability of blood.
目前,根据疟疾暴露风险,欧洲法规要求有疟疾风险的潜在献血者进行 6 个月或 3 年的延期。如果每次献血时免疫或分子基因组检测均为阴性,该期限可缩短至 4 个月,但意大利法规尚未采用该规定。由于在因疟疾而延期 3 年且未经检测的献血者的医学文献中记录了输血传播疟疾的病例,米兰加格里亚大医院的免疫血液学和输血中心决定对所有有疟疾风险的献血者进行免疫检测。
对 412 名有疟疾风险的献血者进行了检测,这些献血者在生命的头 5 年或连续 6 个月以上居住在疟疾流行地区。使用酶免疫分析试剂盒(Malaria EIA,Newmarket,UK)检测疟原虫抗体。该试剂盒使用针对恶性疟原虫和间日疟原虫的 4 种重组抗原,与卵形疟原虫和三日疟原虫有交叉反应。该试剂盒检测针对恶性疟原虫和间日疟原虫的总免疫球蛋白抗体,与卵形疟原虫有 80%的交叉反应,与三日疟原虫有 67%的交叉反应。抗体阳性样本进一步通过免疫层析试验检测恶性疟原虫、间日疟原虫、卵形疟原虫和三日疟原虫抗原以及血涂片(薄血涂片和厚血涂片)进行检查。
意大利公民占受检献血者总数的 16.8%(69/412)。我们发现,8.7%的被归类为有疟疾风险的献血者总免疫球蛋白抗体呈阳性。只有一名意大利公民的检测结果呈阳性。阳性候选者被推迟献血。免疫层析试验和血涂片检查均未发现抗体阳性的献血者呈阳性。
在评估献血者资格时引入疟疾筛查试验可能会提高献血的安全性,但可能会进一步减少血液供应。如果免疫检测被国家接受为评估疟疾风险的有效方法,则目前因疟疾而延期 3 年的 90%以上的献血者可在最后一次访问疫区后 4 个月接受检测,从而增加血液供应。